CK 0803
Alternative Names: CK-0803Latest Information Update: 28 Jul 2025
At a glance
- Originator Cellenkos
- Class Antiparkinsonians; T lymphocyte cell therapies
- Mechanism of Action Regulatory T-lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Amyotrophic lateral sclerosis
- Preclinical Parkinson's disease
- No development reported Chronic inflammatory demyelinating polyradiculoneuropathy
Most Recent Events
- 28 Jul 2025 No recent reports of development identified for preclinical development in Chronic inflammatory demyelinating polyradiculoneuropathy in USA (Parenteral)
- 22 Apr 2025 Efficacy and adverse event data from the phase Ib REGALS trial in Amyotrophic lateral sclerosis released by Cellenkos
- 31 Aug 2023 Preclinical trials in Parkinson's disease in USA (Parenteral) (Cellenkos pipeline, August 2023)